Last updated: May 24, 2026
What clinical trials have been completed or are ongoing for vorinostat (Zolinza)?
Snapshot: Vorinostat is an established HDAC inhibitor with a large historical trial footprint, but current activity is concentrated in (i) combination regimens in oncology and (ii) translational trials targeting biomarker-defined histone deacetylase (HDAC) pathway biology. Near-term incremental clinical upside is most likely from new combination studies using current standard-of-care backbones rather than monotherapy.
Most recent late-stage positioning and the “where trials actually concentrate” pattern
Execution reality for vorinostat:
- The drug reached regulatory approval (US/EU) for cutaneous T-cell lymphoma (CTCL), and subsequent development has largely focused on expanding into additional malignancies through combination trials.
- Most advanced efforts have transitioned toward combinations that pair an HDAC inhibitor with immuno-oncology, chemotherapy, or targeted agents.
Implication for investors and licensors: Trials are less likely to generate a standalone new regulatory indication at scale versus driving label expansion via combination efficacy in biomarker-enriched populations, where endpoints and responder definitions are tighter.
Clinical activity mapping (high-yield taxonomy)
Because the clinical-trial search surface for vorinostat is broad, the trial landscape is best read by intent:
- Oncology combinations (vorinostat + immune checkpoint inhibitors; vorinostat + chemotherapy; vorinostat + targeted oncology agents)
- Biomarker-driven cohorts (HDAC expression signatures, acetylation readouts, histone acetylation markers, and pathway activity)
- Rational schedule optimization (dose frequency, sequencing with companion agents)
- Safety and tolerability refinements in combination settings (thrombocytopenia, fatigue, QT considerations, gastrointestinal events)
Market relevance: These are the trial types most correlated with incremental penetration post-CTCL, because payer coverage and adoption generally track label expansion and evidence strength in standard-of-care contexts.
How is the FDA status of vorinostat and Orange Book listing affecting its commercial future?
Snapshot: Vorinostat is an FDA-approved product (Zolinza, vorinostat). The commercial future is driven by (i) exclusivity and patent coverage in key markets, and (ii) whether new clinical data produce label expansion that re-accelerates demand.
FDA approval baseline
- Vorinostat is approved for cutaneous T-cell lymphoma (CTCL) in the US.
- Any renewed demand catalyst hinges on either additional labeled indications or durable uptake in existing CTCL segments.
Orange Book and generic entry dynamics
- For a marketed oncology drug, the generic/generics timeline is a function of:
- composition-of-matter and method patents,
- formulation and polymorph-related patents (if any), and
- use patents covering dosing regimens or specific patient subgroups.
Commercial impact framework (used for projection models):
- If patents remain active in the US, generic adoption stays limited or delayed.
- If patents expire and no additional barriers exist, pricing pressure starts early and can compress net revenue quickly.
What patents protect vorinostat and how strong is the remaining patent estate?
Snapshot: Vorinostat is an older small molecule. Patent estates for older oncology assets usually thin over time, leaving manufacturing/formulation and method-of-use claims as potential residual barriers. The practical question for projection is whether meaningful US protection persists into the late-2020s.
How the patent estate typically drives revenue trajectories
- If patent coverage is still meaningful: brand pricing resilience extends, and generics enter later.
- If coverage is mostly expired: revenue declines after first generic entry (or authorized generics), typically showing a step-down pattern rather than a linear drift.
- If formulation or method-of-use patents remain enforceable: generic barriers can persist even after composition-of-matter expiry, delaying full substitution.
Key litigation and Paragraph IV risk points
For projection modeling, the main items are:
- Whether any Paragraph IV certifications exist for vorinostat’s reference listed drug product
- Whether there are settlement agreements delaying generic entry
- Whether there are injunction outcomes affecting launch timing
When does vorinostat lose exclusivity in the US and key geographies?
Snapshot: Exclusivity loss determines the timing of revenue compression. For projection purposes, model two phases:
- Pre-first generic: brand holds share; demand follows indication dynamics and tolerability reputation
- Post-entry: pricing falls and net revenue contracts with ramp to multiple generic suppliers
Revenue sensitivity to exclusivity timing
- A shift of even 12 to 18 months in generic launch can materially change cumulative revenue in a projection window through:
- inventory behavior by wholesalers
- payer formularies and step-therapy adoption
- physician prescribing inertia after price breaks
What generic entry risks exist for vorinostat and what launch scenarios matter?
Snapshot: Generic entry risk depends on patent and regulatory status, plus manufacturing readiness. For older oncology small molecules, once approval and patent barriers clear, multiple generics often launch quickly.
Three scenario model for projection
- Single generic entry late: gradual share loss; pricing erosion begins later
- Multiple generics launch quickly: steep pricing compression; faster margin dilution
- Authorized generic + limited patent challenges: earlier share capture with less dispute-based delay
Actionable driver: For market modeling, the highest uncertainty is not scientific but timing. The likely step-change event is generic substitution after barriers fall.
How does vorinostat compare with other HDAC inhibitors in clinical development and uptake?
Snapshot: Vorinostat competes in the HDAC inhibitor class, but practical commercial competition is less about class superiority and more about:
- label position (vorinostat’s CTCL framing historically matters)
- side-effect profile in combinations
- clinician familiarity and payer preferences
- the evidence quality of HDAC inhibitor combinations versus competitors’ differentiated assets
Where comparative evidence tends to decide
- CTCL adoption depends on established clinical outcomes and tolerability in routine practice
- Broader oncology expansion depends on combination response rates and safety manageable at scale
Which companies are developing vorinostat or running major clinical programs?
Snapshot: Development has historically involved multinational oncology research groups and academic centers in combination trial designs. The commercial and licensing landscape is typically a mix of original brand stewardship and later generic competition.
Projection implication: If no new label expansion emerges, market outcomes converge on the exclusivity-and-generic timeline rather than on competitive clinical differentiation.
What is the market size for vorinostat in CTCL and how has it evolved?
Snapshot: Vorinostat’s commercial base is anchored in CTCL. Market size for rare cancers is driven by:
- incidence and prevalence in treated settings
- treatment line availability and sequencing
- physician adoption and payer coverage
- price dynamics after generic entry
Market modeling inputs
A practical projection model uses:
- treated patient count estimates for CTCL in major markets (US, EU5, Japan)
- average annual treatment cost (net of rebates, discounts, payer structures)
- share by line of therapy and patient eligibility
Observed market shape for older oncology brands
In mature oncology products with rare cancer indications:
- demand typically stabilizes for a period post-approval
- net revenue then declines as generics enter or as competing branded/targeted options take share
- the slope steepens after patent cliffs
What revenue projections are most plausible for vorinostat through 2035?
Snapshot: Through 2035, vorinostat’s revenue trajectory is dominated by generic entry timing and any additional label expansion. Without a new large-scale indication, the most credible outcome is sustained CTCL demand followed by post-exclusivity price compression.
Projection framework (high-credibility shape, not optimistic growth)
Phase 1: Near-term (2026–2028)
- Modest growth is possible only if additional uptake catalysts occur (real-world adoption shifts or label reinforcement from new data).
- Otherwise, revenue trends follow pricing and share stability.
Phase 2: Exclusivity transition (late-2028 to mid-2031)
- If generics launch, revenue steps down quickly.
- The magnitude depends on:
- number of entrants
- speed of formulary switches
- rebate/contract re-negotiations
Phase 3: Mature generic era (2031–2035)
- Revenue compresses toward a low-margin generic baseline.
- Brand stewardship remains limited to residual contracts and regions with slower substitution.
What would change the projection most
- A new indication with meaningful scale could reset demand and delay the generic-driven revenue floor.
- Conversely, faster patent erosion or earlier generic entry accelerates the decline.
What formulation, method-of-use, or combination-regimen patents matter for vorinostat?
Snapshot: For many oncology small molecules, remaining IP can cluster in:
- formulation patents (stability, bioavailability improvements, capsule or solid-state specifics)
- method-of-use claims (dosing regimens, sequencing, or combination regimens with specific companion drugs)
- manufacturing method patents
Why this matters for generic competition: Paragraph IV filings often hinge on whether the generic can design around method-of-use claims by altering dosing schedules or combinations. If method claims are strong and enforceable, launch can be delayed.
What manufacturing or supply risks affect vorinostat market performance?
Snapshot: For older oral oncology drugs, supply is usually stable unless:
- multiple sites lose profitability and exit
- raw material sourcing tightens
- regulatory quality issues emerge
Projection link: Supply constraints can temporarily support pricing even after generic entry, but those effects are typically short-lived.
How do pricing, rebates, and payer coverage typically evolve after generic vorinostat entry?
Snapshot: Post-launch economics usually follow a standard pattern:
- increased net price pressure through higher rebate levels
- faster formulary adoption by larger PBMs
- substitution driven by cost controls
Model implication: Even if demand remains stable, net revenue drops due to pricing and rebate compression.
Key Takeaways
- Vorinostat’s clinical future is tied to combination oncology trials and biomarker-defined approaches rather than monotherapy expansion.
- Commercial outcomes through 2035 are primarily a function of US and global patent cliff timing and the speed of generic substitution.
- Projection credibility depends on exclusivity and patent-driven launch timing, with generic-driven step-down as the dominant revenue-shaping event.
- Without a major new indication, market share is likely stable pre-cliff and then declines quickly after generic entry, with mature generic pricing compressing net revenue.
FAQs
1) How many clinical trials listed on ClinicalTrials.gov involve vorinostat in combination therapy?
2) What is the difference between vorinostat use in CTCL and its use in solid tumor trials?
3) Are there biosimilar equivalents for vorinostat, or is it strictly small-molecule generic competition?
4) What dosing schedules of vorinostat are most commonly used in oncology combination trials?
5) Does vorinostat have specific formulation vulnerabilities that affect generic manufacturing approval timing?
References
- FDA. Drug Approval Package: Zolinza (vorinostat). US Food and Drug Administration.
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
- ClinicalTrials.gov. Vorinostat (Search results and study listings). National Library of Medicine.
